Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Irregular Sleep-Wake Rhythm Disorder in Mild to Moderate Alzheimer's Disease Dementia
jRCT2080223437Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of lemborexant in Irregular sleep-wake rhythm disorder (ISWRD) and Alzheimer's disease (AD) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Actigraphy-based nocturnal sleep efficiency. Started Jan 2017; status: completed.
02
Drugs
lemborexant
03
Conditions
Irregular sleep-wake rhythm disorder (ISWRD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223437.